RealFeedApp GSK unveils first functional cure for chronic hepatitis B
The FDA approved bepirovirsen (Hibsago) following two phase 3 clinical trials published in the New England Journal of Medicine. It represents the first functional cure for chronic hepatitis B, suppressing the virus to undetectable levels and maintaining control even after treatment cessation.
- Field
- drugs and trials
- What they did
- The FDA approved the drug bepirovirsen (Hibsago) for treating chronic hepatitis B because it suppresses the virus to undetectable levels and maintains control even after treatment stops.
- Why it matters
- This could save millions of lives, as chronic hepatitis B causes over one million deaths annually and can lead to liver cancer.
#hepatitis b#functional cure#fda approval#bepirovirsen#gsk
